EFFICACY AND SAFETY OF RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT

被引：0
|
作者：
Ali, S. [1 ]
Wakefield, L. A. [1 ]
Saja, K. [1 ]
机构：
[1] Natl Hlth Serv, London, England
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P409
引用
收藏
页码：140 / 140
页数：1
相关论文
共 50 条
  • [21] Comparative Effectiveness, Safety, and Costs of Rivaroxaban and Warfarin Among Morbidly Obese Patients With Non-Valvular Atrial Fibrillation
    Peterson, Eric D.
    Ashton, Veronica
    Chen, Yen-Wen
    Wu, Bingcao
    Mangla, Kamal Kant
    Spyropoulos, Alex C.
    CIRCULATION, 2018, 138
  • [22] Direct comparison of dabigatran, apixaban, rivaroxaban and edoxaban for effectiveness and safety among patients with non-valvular atrial fibrillation
    Choi, E. -K.
    Lee, S. R.
    Kwon, S.
    Han, K. D.
    Jung, J. H.
    Oh, S.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2019, 40 : 2986 - 2986
  • [23] Comparative Effectiveness of Dabigatran and Rivaroxaban versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Bengtson, Lindsay
    Chen, Lin
    MacLehose, Richard
    Lutsey, Pamela
    Alonso, Alvaro
    CIRCULATION, 2014, 130
  • [24] Direct Comparison of Low-Dose Dabigatran and Rivaroxaban for Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation
    Meng, Shih-Wei
    Lin, Ting-Tse
    Liao, Min-Tsun
    Chen, Ho-Min
    Lai, Chao-Lun
    ACTA CARDIOLOGICA SINICA, 2019, 35 (01) : 42 - 54
  • [25] Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
    Liping Zhang
    Xiaoyu Yan
    Keith A. A. Fox
    Stefan Willmann
    Partha Nandy
    Scott D. Berkowitz
    Anne Hermanowski-Vosatka
    Jeffrey I. Weitz
    Alexander Solms
    Stephan Schmidt
    Manesh Patel
    Gary Peters
    Journal of Thrombosis and Thrombolysis, 2020, 50 : 20 - 29
  • [26] Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF
    Jones, William Schuyler
    Hellkamp, Anne S.
    Halperin, Jonathan
    Piccini, Jonathan P.
    Breithardt, Gunter
    Singer, Daniel E.
    Fox, Keith A. A.
    Hankey, Graeme J.
    Mahaffey, Kenneth W.
    Califf, Robert M.
    Patel, Manesh R.
    EUROPEAN HEART JOURNAL, 2014, 35 (04) : 242 - 249
  • [27] Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
    Zhang, Liping
    Yan, Xiaoyu
    Fox, Keith A. A.
    Willmann, Stefan
    Nandy, Partha
    Berkowitz, Scott D.
    Hermanowski-Vosatka, Anne
    Weitz, Jeffrey, I
    Solms, Alexander
    Schmidt, Stephan
    Patel, Manesh
    Peters, Gary
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 50 (01) : 20 - 29
  • [28] Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation
    Singkham, Noppaket
    Phrommintikul, Arintaya
    Pacharasupa, Phongsathon
    Norasetthada, Lalita
    Gunaparn, Siriluck
    Prasertwitayakij, Narawudt
    Wongcharoen, Wanwarang
    Punyawudho, Baralee
    PHARMACEUTICS, 2022, 14 (08)
  • [29] Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation
    Miguel, Luis Silva
    Ferreira, Jorge
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2016, 35 (03) : 141 - 148
  • [30] Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
    Liu, Xiao-qin
    Zhang, Yu-fei
    Ding, Hong-yan
    Yan, Ming-ming
    Jiao, Zheng
    Zhong, Ming-kang
    Ma, Chun-lai
    ACTA PHARMACOLOGICA SINICA, 2022, 43 (10) : 2723 - 2734
12345